A genome-wide association scan on estrogen receptor-negative breast cancer
Authors:
- Jingmei LiJLJingmei Li
- Keith HumphreysKHKeith Humphreys
- Hatef DarabiHDHatef Darabi
- Gustaf RosinGRGustaf Rosin
- Ulf HanneliusUHUlf Hannelius
- Tuomas HeikkinenTHTuomas Heikkinen
- Kristiina AittomäkiKAKristiina Aittomäki
- Carl BlomqvistCBCarl Blomqvist
- Paul Dp PharoahPPPaul Dp Pharoah
- Alison M DunningADAlison M Dunning
- Shahana AhmedSAShahana Ahmed
- Maartje J HooningMHMaartje J Hooning
Open Access
- 9 November 2010
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 12 (6) , R93
Abstract
Introduction: Breast cancer is a heterogeneous disease and may be characterized on the basis of whether estrogen receptors (ER) are expressed in the tumour cells. ER status of breast cancer is important clinically, and is used both as a prognostic indicator and treatment predictor. In this study, we focused on identifying genetic markers associated with ER-negative breast cancer risk.Methods: We conducted a genome-wide association analysis of 285,984 single nucleotide polymorphisms (SNPs) genotyped in 617 ER-negative breast cancer cases and 4,583 controls. We also conducted a genome-wide pathway analysis on the discovery dataset using permutation-based tests on pre-defined pathways. The extent of shared polygenic variation between ER-negative and ER-positive breast cancers was assessed by relating risk scores, derived using ER-positive breast cancer samples, to disease state in independent, ER-negative breast cancer cases.Results: Association with ER-negative breast cancer was not validated for any of the five most strongly associated SNPs followed up in independent studies (1,011 ER-negative breast cancer cases, 7,604 controls). However, an excess of smallP-values for SNPs with known regulatory functions in cancer-related pathways was found (globalP= 0.052). We found no evidence to suggest that ER-negative breast cancer shares a polygenic basis to disease with ER-positive breast cancer.Conclusions: ER-negative breast cancer is a distinct breast cancer subtype that merits independent analyses. Given the clinical importance of this phenotype and the likelihood that genetic effect sizes are small, greater sample sizes and further studies are required to understand the etiology of ER-negative breast cancers.Keywords
This publication has 56 references indexed in Scilit:
- Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2Nature Genetics, 2009
- A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)Nature Genetics, 2009
- Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancerNature Genetics, 2008
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancerNature Genetics, 2007
- A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerNature Genetics, 2007
- A common coding variant in CASP8 is associated with breast cancer riskNature Genetics, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000
- Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and FinlandNew England Journal of Medicine, 2000